Pharmaceutical composition for treating inflammation and pain

Abstract

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a methanesulfonylalkylnitrile compound, or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering a methanesulfonylalkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 5-methanesulfonylpentanenitrile or 7-methanesulfonylheptanenitrile, or a pharmaceutically acceptable solvate thereof. 
     
     
         2 . The pharmaceutical composition of  claim 1 , comprising 7-methanesulfonylheptanenitrile. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, ointments, or patches. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether. 
     
     
         6 . The pharmaceutical composition of  claim 5 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine. 
     
     
         7 . The pharmaceutical composition according to  claim 2 , wherein the compound has at least 90% (w/w) purity, and the composition is in an oral form of tablets or capsules. 
     
     
         8 . The pharmaceutical composition of  claim 1 , comprising 5-methanesulfonylpentanenitrile. 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, ointments, or patches. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil. 
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether. 
     
     
         12 . The pharmaceutical composition of  claim 11 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine. 
     
     
         13 . The pharmaceutical composition according to  claim 9 , wherein the compound has at least 90% (w/w) purity, and the composition is in an oral form of tablets or capsules.